Literature DB >> 33448437

Noninvasive Assessment of Schistosoma-Related Periportal Fibrosis.

Ahmed Hashim1, Annalisa Berzigotti2.   

Abstract

Schistosomiasis affects nearly 250 million individuals in the world. Hepatosplenic schistosomiasis (HSS) results in periportal fibrosis (PPF) and portal hypertension (pHTN). Ultrasound has been extensively used for the diagnosis of Schistosoma-related PPF and a number of staging methods have been validated for this purpose such as Strickland classification and Niamey protocol. Nevertheless, the application of noninvasive techniques, particularly elastography modalities, has not been well explored. In this review, we describe the various noninvasive diagnostic tools for assessment of Schistosoma-related PPF including US parameters, serum biomarkers, and US-based elastography techniques. While elastography techniques have demonstrated value in the evaluation of HSS, the evidence remains limited with most studies recruiting a small number of patients. Longitudinal studies with larger sample size are required in order to devise robust criteria to accurately assess the performance of noninvasive techniques in the prediction of both regression and progression of the degree of PPF and identify their cost-effectiveness in community screening.
© 2021 American Institute of Ultrasound in Medicine.

Entities:  

Keywords:  abdominal ultrasound; elastography; noninvasive assessment; periportal fibrosis; portal hypertension; schistosomiasis

Year:  2021        PMID: 33448437     DOI: 10.1002/jum.15623

Source DB:  PubMed          Journal:  J Ultrasound Med        ISSN: 0278-4297            Impact factor:   2.153


  1 in total

1.  Assessment of periportal fibrosis in Schistosomiasis mansoni patients by proton nuclear magnetic resonance-based metabonomics models.

Authors:  Milena Lima Rodrigues; Tatiane Priscila Santos Rodrigues da Luz; Caroline Louise Diniz Pereira; Andrea Dória Batista; Ana Lúcia Coutinho Domingues; Ricardo Oliveira Silva; Edmundo Pessoa Lopes
Journal:  World J Hepatol       Date:  2022-04-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.